The Trump administration’s back-and-forth messaging over the status of federal funding, which could also impact grant money used by biotechs and pharma companies, has sown confusion and uncertainty.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,